临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2014年
4期
21-23
,共3页
邓良华%莫翠英%吴廷娟%杨子民
鄧良華%莫翠英%吳廷娟%楊子民
산량화%막취영%오정연%양자민
难治性抑郁症%度洛西汀%阿立哌唑%汉密顿抑郁量表%副反应量表
難治性抑鬱癥%度洛西汀%阿立哌唑%漢密頓抑鬱量錶%副反應量錶
난치성억욱증%도락서정%아립고서%한밀돈억욱량표%부반응량표
TRD%duloxetine%aripiprazol%HAMD%TESS
目的:探讨度洛西汀联合阿立哌唑治疗难治性抑郁症的临床疗效和安全性。方法将93例难治性抑郁症患者随机分为两组,研究组口服度洛西汀联合阿立哌唑治疗,对照组单用度洛西汀治疗,观察8周。采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末研究组显效率59.1%、有效率77.3%,对照组分别为31.1%、42.2%,研究组显效率、有效率均显著高于对照组(χ2=7.04、11.35,P<0.01)。两组不良反应较轻微,发生率比较差异无显著性(P>0.05)。结论度洛西汀联合阿立哌唑治疗难治性抑郁症起效快,疗效显著,安全性高,显著优于单用度洛西汀治疗。
目的:探討度洛西汀聯閤阿立哌唑治療難治性抑鬱癥的臨床療效和安全性。方法將93例難治性抑鬱癥患者隨機分為兩組,研究組口服度洛西汀聯閤阿立哌唑治療,對照組單用度洛西汀治療,觀察8週。採用漢密頓抑鬱量錶評定臨床療效,副反應量錶評定不良反應。結果治療8週末研究組顯效率59.1%、有效率77.3%,對照組分彆為31.1%、42.2%,研究組顯效率、有效率均顯著高于對照組(χ2=7.04、11.35,P<0.01)。兩組不良反應較輕微,髮生率比較差異無顯著性(P>0.05)。結論度洛西汀聯閤阿立哌唑治療難治性抑鬱癥起效快,療效顯著,安全性高,顯著優于單用度洛西汀治療。
목적:탐토도락서정연합아립고서치료난치성억욱증적림상료효화안전성。방법장93례난치성억욱증환자수궤분위량조,연구조구복도락서정연합아립고서치료,대조조단용도락서정치료,관찰8주。채용한밀돈억욱량표평정림상료효,부반응량표평정불량반응。결과치료8주말연구조현효솔59.1%、유효솔77.3%,대조조분별위31.1%、42.2%,연구조현효솔、유효솔균현저고우대조조(χ2=7.04、11.35,P<0.01)。량조불량반응교경미,발생솔비교차이무현저성(P>0.05)。결론도락서정연합아립고서치료난치성억욱증기효쾌,료효현저,안전성고,현저우우단용도락서정치료。
Objective To explore the efficacy and safety of duloxetine combined with aripiprazol in the treatment of treatment-resistant depression (TRD) .Meth-ods Ninety-three TRD patients were randomly divided into two groups ,research group (n=47) was trea-ted with oral duloxetine plus aripiprazol and control group (n=46) with single duloxetine for 8 weeks . Clinical efficacies were assessed with the Hamilton Depression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week ,obvious effective and effective rate were respectively 59 .1% and 77 .3% in research and 31 .1% and 42 .2% in control group , the former was significantly than the latter (χ2 = 7 .04 ,11 .35 ;P< 0 .01) .Adverse reactions of both groups were mild ,their incidences had no significant group differences (P>0 .05) .Conclusion Duloxetine plus aripiprazol takes effect more rapidly and has an evident effect and higher safety compared with single duloxetine in the treatment of T RD .